Featured

InTandem is acquiring Healthfuse from New Capital Partners, PE Hub can reveal.

'Investments in niche, non-correlated assets are often smaller in scale, less competitive, and outcomes tend to be more dependent on idiosyncratic factors such as the supply chain for whiskey, the price of carbon, or federally insured crop insurance.'

The KKR complaint says: 'Now, on the eve of a leadership transition, the Antitrust Division has threatened a final act of agency overreach: the imposition of draconian and grossly disproportionate penalties on KKR based on alleged premerger paperwork errors that were immaterial to antitrust clearance.'

'You can’t get there without natural gas power generation.'

'There are half a trillion dollars in distributions that should have happened by now. LPs have been reminding GPs of this fact for a while, increasing pressure for more exits in 2025.'

Audax Private Equity, EQT and NMS Capital are among the PE firms pursuing deals and sales in the clinical trial sector.

'2025 may bring some shifts as we welcome a new administration, potentially influencing areas like trade policies and immigration.'

The surge was propelled by an increase in large deals and greater interest in biopharma and healthcare IT, Nirad Jain said in an exclusive interview with PE Hub.

Epiris' deals in 2024 include the acquisition of Amber Taverns, which operates pubs predominantly in north England.

'Junior capital offers delayed draw capacity, which is a critical source of funding for sponsors with buy-and-build investment strategies seeking to make post-closing acquisitions.'